Propofol and SARS-CoV-2 infection
- PMID: 32928516
- PMCID: PMC7462471
- DOI: 10.1016/j.bja.2020.08.032
Propofol and SARS-CoV-2 infection
Keywords: SARS-CoV-2; antiviral; drug repurposing; outcome; propofol.
Conflict of interest statement
Declarations of interest KH declares no conflicts of interest. DG Lambert is Chairman of BJA.
References
-
- Rodrigues Prestes T.R., Rocha N.P., Miranda A.S., Teixeira A.L., Simoes-E-Silva A.C. The anti-inflammatory potential of ACE2/Angiotensin-(1-7)/Mas receptor axis: evidence from basic and clinical research. Curr Drug Targets. 2017;18:1301–1313. - PubMed
-
- Cao L., Xu L., Huang B., Wu L. Propofol increases angiotensin-converting enzyme 2 expression in human pulmonary artery endothelial cells. Pharmacology. 2012;90:342–347. - PubMed
-
- Reves J.G., Glass P.S.A., Lubarsky D.A., McEvoy M.D., Martinez-Ruiz R. Intravenous anesthetics. In: Miller R.D., Eriksson L.I., Fleisher L.A., Wiener-Kronish J.P., Young W.L., editors. 7th Edn. vol. 1. Churchill Livingstone; Philadelphia, PA: 2009. pp. 719–768. (Miller's anesthesia).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
